Liraglutide

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor stroke or transient ischemic attack, a speaker reported.

The FDA approved a generic version of the GLP-1 receptor agonist liraglutide to improve glycemic control for people with type 2 diabetes, according to a press release from the agency.

The FDA has confirmed there is no longer a shortage of tirzepatide and has set dates for companies to cease distribution of compounded forms of the agent, according to an announcement from the agency.

Patients with alcohol use disorder who used GLP-1 agonists to treat obesity or type 2 diabetes had a decreased risk for hospitalization due to alcohol use disorder, according to a study published in JAMA Psychology.

Ozempic and similar drugs for diabetes and weight-related conditions were associated with a 40% lower rate of opioid overdose and 50% lower rate of alcohol intoxication in people with opioid and alcohol use disorders, a new study showed.

Adolescents with obesity prescribed a GLP-1 receptor agonist are less likely to have suicidal ideation or a suicide attempt than those with obesity treated with lifestyle intervention, according to new data.

Shortages of tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, have been resolved, the FDA announced.

Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications with no significantly higher risk for adverse events, according to findings from a network meta-analysis published in Obesity.

Higher consumption of rye, oats and fruits increased the risk for progression to type 1 diabetes among children at high genetic risk for the disease, study results showed.

Children with obesity receiving once-daily liraglutide 3 mg had a greater reduction in BMI at 56 weeks than those receiving placebo, according to data presented at the European Association for the Study of Diabetes annual meeting.